Vaxcyte, Inc.
PCVX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $5 | $0 | $0 |
| Gross Profit | $0 | -$5 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $210 | $194 | $148 | $134 |
| G&A Expenses | $32 | $32 | $33 | $29 |
| SG&A Expenses | $32 | $32 | $33 | $29 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$5 | $0 | $0 |
| Operating Expenses | $242 | $221 | $181 | $162 |
| Operating Income | -$242 | -$226 | -$181 | -$162 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $30 | $60 | $40 | $25 |
| Pre-Tax Income | -$213 | -$167 | -$141 | -$137 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$213 | -$167 | -$141 | -$137 |
| % Margin | – | – | – | – |
| EPS | -1.56 | -1.22 | -1.04 | -1.12 |
| % Growth | -27.9% | -17.3% | 7.1% | – |
| EPS Diluted | -1.56 | -1.22 | -1.04 | -1.12 |
| Weighted Avg Shares Out | 136 | 136 | 136 | 123 |
| Weighted Avg Shares Out Dil | 136 | 136 | 136 | 123 |
| Supplemental Information | – | – | – | – |
| Interest Income | $29 | $31 | $33 | $36 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $5 | $5 | $5 |
| EBITDA | -$210 | -$162 | -$176 | -$53 |
| % Margin | – | – | – | – |